Meeting
2023 ASCO Annual Meeting
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
Authors
Caicun Zhou
Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Caicun Zhou , Wei Li , Yiping Zhang , Zhengbo Song , Yongsheng Wang , Dingzhi Huang , Feng Ye , Qiming Wang , Yinghui Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05278364
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9111)
DOI
10.1200/JCO.2023.41.16_suppl.9111
Abstract #
9111
Poster Bd #
99
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
First Author: Patrick Schoffski
Poster
2023 ASCO Annual Meeting
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
First Author: Alissa Jamie Cooper
Poster
2022 ASCO Annual Meeting
A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).
First Author: Nathan A. Pennell
Poster
2020 ASCO Virtual Scientific Program
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
First Author: Justin F. Gainor